SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Summary

The study is to explore the efficacy and safety of SCT200 with SCT-I10A or SCT200 combined with paclitaxel/docetaxel in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.

Timeline

Start

2022-06-15

Primary completion

2023-09

Completion

2023-09

Publications

• Lin J, Qu S, Yang K, Zhang T, Bai Y, Wu J, Huang Y, Fang M, Liu X, Huang X, Chen N, Li Z, Li W, Zhang S, Zhang S, Hu G, Sun Y, Chen X, Liu Y, Jing S, Shen L, Chang Z, Xie L, Gai W, Zhou Q, Chen X, Yi J, Guo Y. Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody. Cancer Lett. 2025 Mar 31;613:217513. doi: 10.1016/j.canlet.2025.217513. Epub 2025 Jan 30.

Drugs

Indications